Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | PPARA | Q07869 | 2/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20183469 | 0.96 | MAPT (0.60) | MAPTMEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL10055035 | 0.87 | HPGD (0.67) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL17605113 | 0.86 | MEN1 (0.64) | MAPTMEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL14689659 | 0.85 | MAPT (0.64) | MAPTMEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL30480895 | 0.85 | MAPT (0.64) | MAPTMEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL21722571 | 0.83 | MAPT (0.65) | MAPTMEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL10055018 | 0.82 | NOS1 (0.63) | MAPTMEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL701987 | 0.81 | NLRP3 (0.62) | MAPTMEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL14808999 | 0.81 | MAPT (0.67) | MAPTMEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL16966286 | 0.81 | MAPT (0.59) | MAPTMEN1KMT2AL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121641-B1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | HOFFMANN LA ROCHE (CH) | 2014-09-24 | — | — | EP | disclosed |
| EP-2121641-B1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | HOFFMANN LA ROCHE (CH) | 2014-09-24 | — | — | EP | disclosed |
| US-7902238-B2 | 2-aminooxazolines as TAAR1 ligands | HOFFMANN-LA ROCHE INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902238-B2 | 2-aminooxazolines as TAAR1 ligands | HOFFMANN-LA ROCHE INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902238-B2 | 2-aminooxazolines as TAAR1 ligands | HOFFMANN-LA ROCHE INC. (US) | 2011-03-08 | — | — | US | disclosed |
| CN-101654451-A | N-formyl hydroxylamine compounds as pdf inhibitor | VICURON PHARM INC US | 2010-02-24 | — | — | CN | disclosed |
| EP-2121641-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | F. Hoffmann-Roche AG (CH) | 2009-11-25 | — | — | EP | disclosed |
| US-20090105307-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-23 | — | — | US | disclosed |
| US-20090105307-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-23 | — | — | US | disclosed |
| US-20090105307-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-23 | — | — | US | disclosed |
| WO-2008098857-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008098857-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-21 | — | — | WO | disclosed |
| US-7148242-B2 | N-formyl hydroxylamine compounds, compositions and methods of use | NOVARTIS AG (CH) | 2006-12-12 | — | — | US | disclosed |
| EP-1401828-B1 | N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF | VICURON PHARM INC (US) | 2006-04-12 | — | — | EP | disclosed |
| CN-1511152-A | N-formyl hydroxylamine compounds as PDF inhibitor | ά����ҩ�﹫˾ | 2004-07-07 | — | — | CN | disclosed |
| EP-1401828-A1 | N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF | Vicuron Pharmaceuticals, Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030045479-A1 | Novel N-formyl hydroxylamine compounds, compositions and methods of use | VICURON HOLDINGS LLC | 2003-03-06 | — | — | US | disclosed |
| WO-2002102790-A1 | N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF | VICURON PHARMACEUTICALS INC. (US) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045479-A1 | Novel N-formyl hydroxylamine compounds, compositions and methods of use | PDF, HNMT, AADAC | MAPT 4586/4885MEN1 3262/4885KMT2A 2498/4885 |
| US-20090105307-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | TAAR1, TAAR5, NPSR1 | MAPT 671/4885MEN1 1410/4885KMT2A 1657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.